Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA
Abstract Background To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA...
Main Authors: | Long Zhang, Chaofeng Mu, Tinghong Zhang, Dejun Yang, Chenou Wang, Qiong Chen, Lin Tang, Luhui Fan, Cong Liu, Jianliang Shen, Huaqiong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-020-00758-4 |
Similar Items
-
Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment
by: Liliana-Roxana Balahura Stămat, et al.
Published: (2024-10-01) -
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR
by: Xiaolong Wang, et al.
Published: (2022-08-01) -
Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer
by: Behrad Darvishi, et al.
Published: (2017-06-01) -
Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements
by: Dima Hattab, et al.
Published: (2020-09-01) -
RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
by: Natalia B. Fernández, et al.
Published: (2023-01-01)